The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025 Venus Remedies is targeting the $237-million antibiotic market in GCC region, out of which 35 per cent accounts for
The company has consolidated its position in ASEAN, South America and Eastern Europe regions Venus Remedies has taken another decisive step towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region with the product registration from
The company has consolidated its position in GCC, ASEAN, Balkan and Caribbean regions with marketing approvals from Oman, Malaysia, Bosnia and Trinidad & Tobago for important chemotherapy drugs With this, the number of marketing approvals for its oncology products across 75 countries has gone
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries Venus Remedies has been the largest exporter of meropenem from India in the last three years Riding on the upcoming
The company expects this approval for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of its Carbapenem & Oncology production facilities in Baddi to pave the way for GMP certifications from European Medicines Agency and other Pharmaceutical Inspection
Marking a major step in the global expansion strategy of Venus Remedies through its oncology products, this marketing authorisation from the largest GCC market will enable Venus Remedies to establish a strong foothold in GCC and MENA regions In a decisive step towards making its
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans Venus Remedies Limited, a leading research-based pharmaceutical company, has achieved another significant milestone by securing a Good Manufacturing Practices (GMP) certification from